Ignite Creation Date:
2025-12-24 @ 12:38 PM
Ignite Modification Date:
2025-12-28 @ 9:24 AM
Study NCT ID:
NCT01186861
Status:
COMPLETED
Last Update Posted:
2025-11-18
First Post:
2010-08-19
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy
Sponsor:
Astellas Pharma Inc
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2011-03-04
Start Date Type:
ACTUAL
Primary Completion Date:
2013-07-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2015-03-11
Completion Date Type:
ACTUAL
First Submit Date:
2010-08-19
First Submit QC Date:
None
Study First Post Date:
2010-08-23
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2014-06-23
Disp First Post Date Type:
ESTIMATED
Last Update Submit Date:
2025-11-13
Last Update Post Date:
2025-11-18
Last Update Post Date Type:
ESTIMATED